← Back to Search

Radiation Therapy

Stereotactic ablative radiotherapy for Prostate Cancer (SATURN Trial)

Phase 1 & 2
Waitlist Available
Led By Andrew Loblaw, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

SATURN Trial Summary

This trial is testing a new way to give radiation to prostate cancer patients that may be more effective with fewer side effects.

Eligible Conditions
  • Prostate Cancer

SATURN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acute GU and GI toxicities
Secondary outcome measures
Biochemical control
Disease
Late GU and GI toxicities
+1 more

SATURN Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic ablative radiotherapyExperimental Treatment1 Intervention
40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic ablative radiotherapy
2012
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
659 Previous Clinical Trials
1,551,602 Total Patients Enrolled
34 Trials studying Prostate Cancer
12,608 Patients Enrolled for Prostate Cancer
Andrew Loblaw, MDPrincipal InvestigatorSunnybrook Health Sciences Centre/University of Toronto
7 Previous Clinical Trials
510 Total Patients Enrolled
6 Trials studying Prostate Cancer
358 Patients Enrolled for Prostate Cancer
~3 spots leftby Jun 2025